RxDoctor Payments Data

Kimberly Quick, MD

Cardiovascular Disease · Safety Harbor, FLNPI 1851342885

Payments from drug & device makers

$3,596in general payments, 2019–2025

Across 201 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$466
  • Johnson & Johnson$452
  • Pfizer$417
  • Amgen$357
  • Abbott$228
  • E.r. Squibb & Sons, L.L.C.$200
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,589100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,596 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$343,692
Medicare patients
1,410
Services billed
3,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban250$302,424
EliquisApixaban233$296,943
EntrestoSacubitril/Valsartan88$105,420
Repatha SureclickEvolocumab47$40,036
BrilintaTicagrelor15$19,704
Repatha SyringeEvolocumab12$6,629
Metoprolol Succinate376$5,129
Atorvastatin Calcium441$4,269
Losartan Potassium269$2,665
Rosuvastatin Calcium197$2,578
Ezetimibe64$2,115
ClopidogrelClopidogrel Bisulfate162$2,008
Nebivolol Hcl24$1,947
Carvedilol192$1,930
Metoprolol Tartrate289$1,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$452$302,424250 claims
PfizerEliquis$417$296,943233 claims
NovartisEntresto$466$105,42088 claims
AstraZenecaBrilinta$168$19,70415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Safety Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →